Abstract
S2308 is a study comparing rituximab, which is not the standard of care, to.mosunetuzumab-axgb, a first-in-class CD20-directed CD3 T-cell engager with.unknown long term side effects, in a heterogeneous patient population in which a fifth.of patients do not need treatment for at least 10 years. The treatment of asymptomatic.low tumor burden follicular lymphoma is watchful waiting and no treatment has.demonstrated improvement in OS after long term follow up. Beyond the limitations of.the study design, this study would be the basis of regulatory approval and cooperative.groups receiving federal funding should not be running this trial. Study sites are USbased.and mostly include community oncology practices, risking inclusion of very low.risk patients that are most likely to be harmed by any treatment.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call